tiprankstipranks
Trending News
More News >
Agilon Health Inc (AGL)
NYSE:AGL
US Market

Agilon Health (AGL) Stock Forecast & Price Target

Compare
363 Followers
See the Price Targets and Ratings of:

AGL Analyst Ratings

Hold
10Ratings
Hold
1 Buy
7 Hold
2 Sell
Based on 10 analysts giving stock ratings to
Agilon
Health
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

AGL Stock 12 Month Forecast

Average Price Target

$0.71
▲(10.94% Upside)
Based on 10 Wall Street analysts offering 12 month price targets for Agilon Health in the last 3 months. The average price target is $0.71 with a high forecast of $0.88 and a low forecast of $0.50. The average price target represents a 10.94% change from the last price of $0.64.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","5":"$5","-1":"-$1","0.5":"$0.5","3.5":"$3.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":0.88,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$0.88</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":0.71,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$0.71</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":0.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$0.50</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,0.5,2,3.5,5],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2025","6":"Sep<br/>2025","9":"Dec<br/>2025","12":"Mar<br/>2026","25":"Mar<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.615,0.6353846153846153,0.6557692307692308,0.6761538461538461,0.6965384615384616,0.7169230769230769,0.7373076923076923,0.7576923076923077,0.7780769230769231,0.7984615384615384,0.8188461538461539,0.8392307692307692,0.8596153846153847,{"y":0.88,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.615,0.6223076923076923,0.6296153846153846,0.6369230769230769,0.6442307692307692,0.6515384615384615,0.6588461538461539,0.6661538461538461,0.6734615384615384,0.6807692307692308,0.688076923076923,0.6953846153846154,0.7026923076923076,{"y":0.71,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.615,0.6061538461538462,0.5973076923076923,0.5884615384615385,0.5796153846153846,0.5707692307692308,0.561923076923077,0.553076923076923,0.5442307692307692,0.5353846153846153,0.5265384615384615,0.5176923076923077,0.5088461538461538,{"y":0.5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.12,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.08,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.93,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.25,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.38,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.7,"date":1754006400000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 9</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.27,"date":1756684800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 9</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1,"date":1759276800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 34, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 14</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.796,"date":1761955200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 34, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 15</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.622,"date":1764547200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 36, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 16</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.688,"date":1767225600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 38, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 12</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.827,"date":1769904000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 58, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 15</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.615,"date":1772323200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 70, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 17</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$0.88Average Price Target$0.71Lowest Price Target$0.50
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Truist Financial Analyst forecast on AGL
Truist Financial
Truist Financial
Hold
Reiterated
03/04/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Agilon Health (NYSE: AGL), Arcturus Therapeutics (NASDAQ: ARCT) and ImmunityBio (NASDAQ: IBRX)
Citi
$0.85$0.75
Hold
17.19%
Upside
Reiterated
03/03/26
Agilon Health price target lowered to 75c from 85c at CitiAgilon Health price target lowered to 75c from 85c at Citi
Barclays
$0.5
Sell
-21.88%
Downside
Reiterated
02/27/26
Agilon Health (AGL) Receives a Sell from Barclays
TD Cowen
$0.6
Hold
-6.25%
Downside
Reiterated
02/27/26
Hold Rating on Agilon: Margin Improvement Efforts Tempered by Persistent Profitability and Cost Pressures
Bank of America Securities Analyst forecast on AGL
Bank of America Securities
Bank of America Securities
Sell
Reiterated
02/26/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Agilon Health (NYSE: AGL), MiMedx Group (NASDAQ: MDXG) and Park Dental Partners, Inc. (NASDAQ: PARK)
Evercore ISI
$0.8
Hold
25.00%
Upside
Reiterated
02/26/26
Evercore ISI Sticks to Their Hold Rating for Agilon Health (AGL)
Needham
Hold
Reiterated
02/26/26
Analysts Offer Insights on Healthcare Companies: Agilent (NYSE: A), Agilon Health (NYSE: AGL) and Sarepta Therapeutics (NASDAQ: SRPT)
William Blair Analyst forecast on AGL
William Blair
William Blair
Hold
Reiterated
02/25/26
Analysts Conflicted on These Healthcare Names: Alector (NASDAQ: ALEC), Agilon Health (NYSE: AGL) and Pennant Group (NASDAQ: PNTG)
RBC Capital
Buy
Reiterated
02/08/26
Analysts Offer Insights on Healthcare Companies: Inotiv (NASDAQ: NOTV) and Agilon Health (NYSE: AGL)
Bernstein Analyst forecast on AGL
Bernstein
Bernstein
$0.88
Hold
37.50%
Upside
Reiterated
01/27/26
Analysts Offer Insights on Healthcare Companies: Agilon Health (NYSE: AGL), Vera Therapeutics (NASDAQ: VERA) and Molina Healthcare (NYSE: MOH)
Benchmark Co. Analyst forecast on AGL
Benchmark Co.
Benchmark Co.
$1.5
Buy
134.38%
Upside
Reiterated
11/06/25
Agilon Health (AGL) Receives a Buy from Benchmark Co.
BTIG
Hold
Assigned
11/04/25
Agilon Health: Hold Rating Amid Cost Pressures and Uncertain Turnaround Efforts
Wells Fargo Analyst forecast on AGL
Wells Fargo
Wells Fargo
$5$1.5
Buy
134.38%
Upside
Reiterated
10/06/25
Agilon Health price target lowered to $1.50 from $5 at Wells FargoAgilon Health price target lowered to $1.50 from $5 at Wells Fargo
J.P. Morgan Analyst forecast on AGL
J.P. Morgan
J.P. Morgan
Hold
Reiterated
08/22/25
Balanced Outlook for Agilon Health Amid Market Stability and Challenges
Jefferies Analyst forecast on AGL
Jefferies
Jefferies
$2.4$1.1
Hold
71.88%
Upside
Reiterated
08/15/25
Agilon Health Faces Leadership and Performance Challenges Amid Hold Rating
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Truist Financial Analyst forecast on AGL
Truist Financial
Truist Financial
Hold
Reiterated
03/04/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Agilon Health (NYSE: AGL), Arcturus Therapeutics (NASDAQ: ARCT) and ImmunityBio (NASDAQ: IBRX)
Citi
$0.85$0.75
Hold
17.19%
Upside
Reiterated
03/03/26
Agilon Health price target lowered to 75c from 85c at CitiAgilon Health price target lowered to 75c from 85c at Citi
Barclays
$0.5
Sell
-21.88%
Downside
Reiterated
02/27/26
Agilon Health (AGL) Receives a Sell from Barclays
TD Cowen
$0.6
Hold
-6.25%
Downside
Reiterated
02/27/26
Hold Rating on Agilon: Margin Improvement Efforts Tempered by Persistent Profitability and Cost Pressures
Bank of America Securities Analyst forecast on AGL
Bank of America Securities
Bank of America Securities
Sell
Reiterated
02/26/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Agilon Health (NYSE: AGL), MiMedx Group (NASDAQ: MDXG) and Park Dental Partners, Inc. (NASDAQ: PARK)
Evercore ISI
$0.8
Hold
25.00%
Upside
Reiterated
02/26/26
Evercore ISI Sticks to Their Hold Rating for Agilon Health (AGL)
Needham
Hold
Reiterated
02/26/26
Analysts Offer Insights on Healthcare Companies: Agilent (NYSE: A), Agilon Health (NYSE: AGL) and Sarepta Therapeutics (NASDAQ: SRPT)
William Blair Analyst forecast on AGL
William Blair
William Blair
Hold
Reiterated
02/25/26
Analysts Conflicted on These Healthcare Names: Alector (NASDAQ: ALEC), Agilon Health (NYSE: AGL) and Pennant Group (NASDAQ: PNTG)
RBC Capital
Buy
Reiterated
02/08/26
Analysts Offer Insights on Healthcare Companies: Inotiv (NASDAQ: NOTV) and Agilon Health (NYSE: AGL)
Bernstein Analyst forecast on AGL
Bernstein
Bernstein
$0.88
Hold
37.50%
Upside
Reiterated
01/27/26
Analysts Offer Insights on Healthcare Companies: Agilon Health (NYSE: AGL), Vera Therapeutics (NASDAQ: VERA) and Molina Healthcare (NYSE: MOH)
Benchmark Co. Analyst forecast on AGL
Benchmark Co.
Benchmark Co.
$1.5
Buy
134.38%
Upside
Reiterated
11/06/25
Agilon Health (AGL) Receives a Buy from Benchmark Co.
BTIG
Hold
Assigned
11/04/25
Agilon Health: Hold Rating Amid Cost Pressures and Uncertain Turnaround Efforts
Wells Fargo Analyst forecast on AGL
Wells Fargo
Wells Fargo
$5$1.5
Buy
134.38%
Upside
Reiterated
10/06/25
Agilon Health price target lowered to $1.50 from $5 at Wells FargoAgilon Health price target lowered to $1.50 from $5 at Wells Fargo
J.P. Morgan Analyst forecast on AGL
J.P. Morgan
J.P. Morgan
Hold
Reiterated
08/22/25
Balanced Outlook for Agilon Health Amid Market Stability and Challenges
Jefferies Analyst forecast on AGL
Jefferies
Jefferies
$2.4$1.1
Hold
71.88%
Upside
Reiterated
08/15/25
Agilon Health Faces Leadership and Performance Challenges Amid Hold Rating
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Agilon Health

3 Months
xxx
Success Rate
5/9 ratings generated profit
56%
Average Return
+13.49%
reiterated a xxx
rating 19 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 55.56% of your transactions generating a profit, with an average return of +13.49% per trade.
1 Year
Success Rate
8/9 ratings generated profit
89%
Average Return
+49.82%
reiterated a sell rating 19 days ago
Copying Andrew Mok CFA's trades and holding each position for 1 Year would result in 88.89% of your transactions generating a profit, with an average return of +49.82% per trade.
2 Years
xxx
Success Rate
8/9 ratings generated profit
89%
Average Return
+61.36%
reiterated a xxx
rating 19 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 88.89% of your transactions generating a profit, with an average return of +61.36% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

AGL Analyst Recommendation Trends

Rating
Nov 25
Dec 25
Jan 26
Feb 26
Mar 26
Strong Buy
1
1
1
0
0
Buy
2
1
0
0
0
Hold
34
36
38
58
70
Sell
15
16
12
15
17
Strong Sell
0
0
0
0
0
total
52
54
51
73
87
In the current month, AGL has received 0 Buy Ratings, 70 Hold Ratings, and 17 Sell Ratings. AGL average Analyst price target in the past 3 months is 0.71.
Each month's total comprises the sum of three months' worth of ratings.

AGL Financial Forecast

AGL Earnings Forecast

Next quarter’s earnings estimate for AGL is $0.06 with a range of $0.02 to $0.23. The previous quarter’s EPS was -$0.46. AGL beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year AGL has Performed in-line its overall industry.
Next quarter’s earnings estimate for AGL is $0.06 with a range of $0.02 to $0.23. The previous quarter’s EPS was -$0.46. AGL beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year AGL has Performed in-line its overall industry.

AGL Sales Forecast

Next quarter’s sales forecast for AGL is $1.41B with a range of $1.36B to $1.62B. The previous quarter’s sales results were $1.57B. AGL beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year AGL has Performed in-line its overall industry.
Next quarter’s sales forecast for AGL is $1.41B with a range of $1.36B to $1.62B. The previous quarter’s sales results were $1.57B. AGL beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year AGL has Performed in-line its overall industry.

AGL Stock Forecast FAQ

What is AGL’s average 12-month price target, according to analysts?
Based on analyst ratings, Agilon Health Inc’s 12-month average price target is 0.71.
    What is AGL’s upside potential, based on the analysts’ average price target?
    Agilon Health Inc has 10.94% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is AGL a Buy, Sell or Hold?
          Agilon Health Inc has a consensus rating of Hold which is based on 1 buy ratings, 7 hold ratings and 2 sell ratings.
            What is Agilon Health Inc’s price target?
            The average price target for Agilon Health Inc is 0.71. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $0.88 ,the lowest forecast is $0.50. The average price target represents 10.94% Increase from the current price of $0.64.
              What do analysts say about Agilon Health Inc?
              Agilon Health Inc’s analyst rating consensus is a Hold. This is based on the ratings of 10 Wall Streets Analysts.
                How can I buy shares of AGL?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.